Pharsight

Drugs that contain Viloxazine Hydrochloride

1. Qelbree patents expiration

QELBREE Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11458143 SUPERNUS PHARMS NA
Sep, 2029

(5 years from now)

US11324753 SUPERNUS PHARMS Method of treatment of attention deficit/hyperactivity disorder (ADHD)
Sep, 2029

(5 years from now)

US9358204 SUPERNUS PHARMS Formulations of viloxazine
Feb, 2033

(8 years from now)

US9603853 SUPERNUS PHARMS Formulations of viloxazine
Feb, 2033

(8 years from now)

US9662338 SUPERNUS PHARMS Formulations of viloxazine
Feb, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 2, 2026
New Patient Population (NPP) Apr 29, 2025

NCE-1 date: 2025-04-02

Market Authorisation Date: 02 April, 2021

Treatment: U-727: for the treatment of attention deficit hyperactivity disorder (adhd); For the treatment of attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage

QELBREE family patents

Family Patents